VA
VR Adviser Portfolio holdings
AUM
$1.33B
This Quarter Return
-16.23%
1 Year Return
+6.92%
3 Year Return
+862.77%
5 Year Return
+1,580.48%
10 Year Return
–
AUM
$1.57B
AUM Growth
+$1.57B
(-25%)
Cap. Flow
-$35.2M
Cap. Flow
% of AUM
-2.24%
Top 10 Holdings %
Top 10 Hldgs %
64.59%
Holding
44
New
6
Increased
6
Reduced
3
Closed
9
Top Buys
| 1 |
Erasca
ERAS
|
$38.3M |
| 2 |
Cullinan Oncology
CGEM
|
$24.1M |
| 3 |
Zura Bio
ZURA
|
$21.1M |
| 4 |
Spyre Therapeutics
SYRE
|
$12.1M |
| 5 |
PCSC
Perceptive Capital Solutions Corp Class A Ordinary Shares
PCSC
|
$7.55M |
Top Sells
| 1 |
HilleVax
HLVX
|
$34.5M |
| 2 |
Merus
MRUS
|
$31.2M |
| 3 |
Celcuity
CELC
|
$21M |
| 4 |
Immatics
IMTX
|
$18.4M |
| 5 |
Lyra Therapeutics
LYRA
|
$16M |
Sector Composition
| 1 | Healthcare | 99.52% |
| 2 | Financials | 0.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Apogee Therapeutics
APGE
$2.17B
| $334M | 21.28% | 8,493,321 | – | – |
|
2
Enliven Therapeutics
ELVN
$1.2B
| $94.1M | 5.99% | 4,026,331 | – | – |
|
3
4D Molecular Therapeutics
FDMT
$288M
| $92.4M | 5.88% | 4,400,000 | – | – |
|
4
Ocular Therapeutix
OCUL
$2.12B
| $87.3M | 5.56% | 12,762,462 | – | – |
|
5
Dyne Therapeutics
DYN
$1.92B
| $76.7M | 4.89% | 2,173,913 | – | – |
|
|
6
Merus
MRUS
$4.98B
| $74.7M | 4.76% | 1,263,214 -527,000 | -29% | -$31.2M |
|
7
KalVista Pharmaceuticals
KALV
$678M
| $73.6M | 4.69% | 6,249,731 | – | – |
|
8
Pharvaris
PHVS
$1.39B
| $63.8M | 4.07% | 3,395,606 | – | – |
|
|
9
Spyre Therapeutics
SYRE
$996M
| $63.1M | 4.02% | 2,685,448 +513,666 | +24% | +$12.1M |
|
10
Dianthus Therapeutics
DNTH
$759M
| $54.2M | 3.45% | 2,094,373 | – | – |
|
11
Viridian Therapeutics
VRDN
$1.5B
| $50.5M | 3.22% | 3,882,671 | – | – |
|
12
Cogent Biosciences
COGT
$1.69B
| $47.9M | 3.05% | 5,684,167 +555,000 | +11% | +$4.68M |
|
13
Applied Therapeutics
APLT
$71M
| $44.6M | 2.84% | 9,542,871 +467,871 | +5% | +$2.18M |
|
|
14
Erasca
ERAS
$445M
| $38.3M | 2.44% | +16,216,216 | New | +$38.3M |
|
15
Astria Therapeutics
ATXS
$349M
| $32.8M | 2.09% | 3,608,645 | – | – |
|
16
Edgewise Therapeutics
EWTX
$1.51B
| $32.7M | 2.09% | 1,818,182 | – | – |
|
17
Oric Pharmaceuticals
ORIC
$994M
| $31.1M | 1.98% | 4,394,527 | – | – |
|
18
Praxis Precision Medicines
PRAX
$958M
| $29.2M | 1.86% | 706,131 +5 | +0% | +$207 |
|
19
enGene Holdings
ENGN
$236M
| $26.6M | 1.7% | 2,825,983 +260,142 | +10% | +$2.45M |
|
|
20
Cullinan Oncology
CGEM
$445M
| $24.1M | 1.53% | +1,379,965 | New | +$24.1M |
|
21
Terns Pharmaceuticals
TERN
$609M
| $23.2M | 1.48% | 3,410,058 | – | – |
|
22
Mersana Therapeutics
MRSN
$36.5M
| $22.8M | 1.45% | 11,328,000 | – | – |
|
|
23
Zura Bio
ZURA
$133M
| $21.1M | 1.34% | +6,023,166 | New | +$21.1M |
|
24
Taysha Gene Therapies
TSHA
$797M
| $20.2M | 1.28% | 9,000,000 | – | – |
|
|
ABVX
25
Abivax
ABVX
$6.12B
| $17.8M | 1.13% | 1,345,780 | – | – |
|